25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ALT (Altimmune) Stock Analysis
Buy, Hold or Sell?

Let's analyze Altimmune together

I guess you are interested in Altimmune Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Altimmune’s Financial Insights
  • 📈 Technical Analysis (TA) – Altimmune’s Price Targets

I'm going to help you getting a better view of Altimmune Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Altimmune Inc

I send you an email if I find something interesting about Altimmune Inc.

1. Quick Overview

1.1. Quick analysis of Altimmune (30 sec.)










1.2. What can you expect buying and holding a share of Altimmune? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
12.5%

What is your share worth?

Current worth
$1.75
Expected worth in 1 year
$1.37
How sure are you?
45.0%

+ What do you gain per year?

Total Gains per Share
$-0.38
Return On Investment
-5.4%

For what price can you sell your share?

Current Price per Share
$7.03
Expected price per share
$5.15 - $7.83
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Altimmune (5 min.)




Live pricePrice per Share (EOD)
$7.03
Intrinsic Value Per Share
$-9.28 - $-4.41
Total Value Per Share
$-7.53 - $-2.66

2.2. Growth of Altimmune (5 min.)




Is Altimmune growing?

Current yearPrevious yearGrowGrow %
How rich?$142.1m$171.2m-$33.3m-24.2%

How much money is Altimmune making?

Current yearPrevious yearGrowGrow %
Making money-$22.5m-$23.1m$631.7k2.8%
Net Profit Margin-451,200.0%-211,697.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Altimmune (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#297 / 887

Most Revenue
#630 / 887

Most Profit
#668 / 887

Most Efficient
#885 / 887
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Altimmune?

Welcome investor! Altimmune's management wants to use your money to grow the business. In return you get a share of Altimmune.

First you should know what it really means to hold a share of Altimmune. And how you can make/lose money.

Speculation

The Price per Share of Altimmune is $7.03. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Altimmune.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Altimmune, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.75. Based on the TTM, the Book Value Change Per Share is $-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Altimmune.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.24-3.4%-0.28-4.0%-0.29-4.1%-0.28-3.9%-0.27-3.8%-0.11-1.6%
Usd Book Value Change Per Share0.233.3%-0.09-1.3%0.020.2%-0.04-0.6%0.060.9%0.040.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.081.2%10.02142.5%
Usd Total Gains Per Share0.233.3%-0.09-1.3%0.020.2%-0.04-0.6%0.152.1%10.06143.0%
Usd Price Per Share5.00-6.25-6.89-8.14-9.17-9.36-
Price to Earnings Ratio-5.18--5.60--5.67--7.30--9.27--32.65-
Price-to-Total Gains Ratio21.74--22.49--3,984.07--1,326.37--805.73--560.00-
Price to Book Ratio2.85-3.71-3.15-3.88-4.28-18.37-
Price-to-Total Gains Ratio21.74--22.49--3,984.07--1,326.37--805.73--560.00-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.03
Number of shares142
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.08
Usd Book Value Change Per Share-0.090.06
Usd Total Gains Per Share-0.090.15
Gains per Quarter (142 shares)-13.4720.64
Gains per Year (142 shares)-53.8882.54
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-54-64473573
20-108-1189570156
30-162-172142105239
40-216-226190140322
50-269-280237176405
60-323-334285211488
70-377-388332246571
80-431-442379281654
90-485-496427316737
100-539-550474351820

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%3.037.00.07.5%12.067.00.015.2%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%8.012.00.040.0%14.024.02.035.0%32.045.02.040.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%1.00.019.05.0%5.00.035.012.5%6.00.073.07.6%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%8.012.00.040.0%18.022.00.045.0%36.043.00.045.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Altimmune Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.230-0.095+141%0.016+1334%-0.044+119%0.062+272%0.038+511%
Book Value Per Share--1.7531.700+3%2.112-17%2.044-14%2.204-20%1.365+28%
Current Ratio--15.84614.282+11%15.379+3%14.088+12%16.226-2%12.375+28%
Debt To Asset Ratio--0.0960.107-10%0.086+12%0.095+1%0.101-5%0.157-39%
Debt To Equity Ratio--0.1060.120-11%0.094+13%0.105+1%0.114-7%0.428-75%
Dividend Per Share----0%-0%-0%0.084-100%10.017-100%
Enterprise Value--540260000.000636869750.000-15%713035230.000-24%810114741.667-33%900728091.700-40%846899450.100-36%
Eps---0.241-0.278+15%-0.286+18%-0.276+14%-0.265+10%-0.111-54%
Ev To Ebitda Ratio---6.678-7.007+5%-7.228+8%-8.832+32%-11.062+66%-72.908+992%
Ev To Sales Ratio--27013.00031843.488-15%18794.876+44%32673.321-17%20087.487+34%10556.788+156%
Free Cash Flow Per Share---0.208-0.248+19%-0.224+8%-0.228+10%-0.220+6%-0.062-70%
Free Cash Flow To Equity Per Share--0.213-0.111+152%0.041+416%-0.039+118%0.067+216%0.107+99%
Gross Profit Margin--1.0001.0020%1.016-2%1.006-1%1.0040%1.0020%
Intrinsic Value_10Y_max---4.414----------
Intrinsic Value_10Y_min---9.283----------
Intrinsic Value_1Y_max---0.275----------
Intrinsic Value_1Y_min---0.920----------
Intrinsic Value_3Y_max---0.955----------
Intrinsic Value_3Y_min---2.790----------
Intrinsic Value_5Y_max---1.787----------
Intrinsic Value_5Y_min---4.673----------
Market Cap570182210.000+29%405535000.000506918750.000-20%558827230.000-27%660346158.333-39%743872850.500-45%759465671.250-47%
Net Profit Margin---3915.000-4512.000+15%-2116.974-46%-3456.597-12%-2126.809-46%-1092.152-72%
Operating Margin---4051.000-4545.600+12%-2242.829-45%-3513.415-13%-2161.011-47%-1123.464-72%
Operating Ratio--4364.0004915.350-11%2916.215+50%4932.834-12%3027.247+44%1620.443+169%
Pb Ratio4.011+29%2.8533.714-23%3.146-9%3.884-27%4.285-33%18.371-84%
Pe Ratio-7.282-41%-5.179-5.602+8%-5.670+9%-7.297+41%-9.270+79%-32.650+530%
Price Per Share7.030+29%5.0006.250-20%6.890-27%8.142-39%9.172-45%9.364-47%
Price To Free Cash Flow Ratio-8.465-41%-6.020-6.516+8%-8.171+36%-9.475+57%-11.914+98%-22.754+278%
Price To Total Gains Ratio30.566+29%21.740-22.486+203%-3984.075+18426%-1326.373+6201%-805.727+3806%-560.000+2676%
Quick Ratio--25.62323.700+8%20.841+23%20.334+26%21.580+19%16.818+52%
Return On Assets---0.124-0.147+18%-0.123-1%-0.123-1%-0.113-9%-0.074-40%
Return On Equity---0.138-0.165+20%-0.134-2%-0.136-1%-0.126-8%-0.004-97%
Total Gains Per Share--0.230-0.095+141%0.016+1334%-0.044+119%0.145+58%10.055-98%
Usd Book Value--142162000.000137894500.000+3%171286750.000-17%165776166.667-14%178770005.350-20%110728345.200+28%
Usd Book Value Change Per Share--0.230-0.095+141%0.016+1334%-0.044+119%0.062+272%0.038+511%
Usd Book Value Per Share--1.7531.700+3%2.112-17%2.044-14%2.204-20%1.365+28%
Usd Dividend Per Share----0%-0%-0%0.084-100%10.017-100%
Usd Enterprise Value--540260000.000636869750.000-15%713035230.000-24%810114741.667-33%900728091.700-40%846899450.100-36%
Usd Eps---0.241-0.278+15%-0.286+18%-0.276+14%-0.265+10%-0.111-54%
Usd Free Cash Flow---16840000.000-20082750.000+19%-18189000.000+8%-18476833.333+10%-17810036.250+6%-5002169.275-70%
Usd Free Cash Flow Per Share---0.208-0.248+19%-0.224+8%-0.228+10%-0.220+6%-0.062-70%
Usd Free Cash Flow To Equity Per Share--0.213-0.111+152%0.041+416%-0.039+118%0.067+216%0.107+99%
Usd Market Cap570182210.000+29%405535000.000506918750.000-20%558827230.000-27%660346158.333-39%743872850.500-45%759465671.250-47%
Usd Price Per Share7.030+29%5.0006.250-20%6.890-27%8.142-39%9.172-45%9.364-47%
Usd Profit---19575000.000-22560000.000+15%-23191750.000+18%-22103916.667+13%-21342882.600+9%-8638217.900-56%
Usd Revenue--5000.0005000.0000%102500.000-95%29250.000-83%538284.450-99%1085920.125-100%
Usd Total Gains Per Share--0.230-0.095+141%0.016+1334%-0.044+119%0.145+58%10.055-98%
 EOD+6 -2MRQTTM+28 -9YOY+19 -193Y+19 -195Y+20 -2010Y+16 -24

3.3 Fundamental Score

Let's check the fundamental score of Altimmune Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.282
Price to Book Ratio (EOD)Between0-14.011
Net Profit Margin (MRQ)Greater than0-3,915.000
Operating Margin (MRQ)Greater than0-4,051.000
Quick Ratio (MRQ)Greater than125.623
Current Ratio (MRQ)Greater than115.846
Debt to Asset Ratio (MRQ)Less than10.096
Debt to Equity Ratio (MRQ)Less than10.106
Return on Equity (MRQ)Greater than0.15-0.138
Return on Assets (MRQ)Greater than0.05-0.124
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Altimmune Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5066.625
Ma 20Greater thanMa 506.084
Ma 50Greater thanMa 1005.535
Ma 100Greater thanMa 2005.715
OpenGreater thanClose6.850
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Fundamental data was last updated by Penke on 2025-06-18 23:00:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Altimmune earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • A Net Profit Margin of -391,500.0% means that $-3,915.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Altimmune Inc:

  • The MRQ is -391,500.0%. The company is making a huge loss. -2
  • The TTM is -451,200.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-391,500.0%TTM-451,200.0%+59,700.0%
TTM-451,200.0%YOY-211,697.4%-239,502.6%
TTM-451,200.0%5Y-212,680.9%-238,519.1%
5Y-212,680.9%10Y-109,215.2%-103,465.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-391,500.0%-92.7%-391,407.3%
TTM-451,200.0%-142.2%-451,057.8%
YOY-211,697.4%-187.4%-211,510.0%
3Y-345,659.7%-248.5%-345,411.2%
5Y-212,680.9%-344.1%-212,336.8%
10Y-109,215.2%-479.9%-108,735.3%
4.3.1.2. Return on Assets

Shows how efficient Altimmune is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • -12.4% Return on Assets means that Altimmune generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Altimmune Inc:

  • The MRQ is -12.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.4%TTM-14.7%+2.2%
TTM-14.7%YOY-12.3%-2.4%
TTM-14.7%5Y-11.3%-3.4%
5Y-11.3%10Y-7.4%-3.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.4%-11.3%-1.1%
TTM-14.7%-11.2%-3.5%
YOY-12.3%-11.0%-1.3%
3Y-12.3%-11.6%-0.7%
5Y-11.3%-11.8%+0.5%
10Y-7.4%-13.7%+6.3%
4.3.1.3. Return on Equity

Shows how efficient Altimmune is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • -13.8% Return on Equity means Altimmune generated $-0.14 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Altimmune Inc:

  • The MRQ is -13.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.8%TTM-16.5%+2.7%
TTM-16.5%YOY-13.4%-3.0%
TTM-16.5%5Y-12.6%-3.8%
5Y-12.6%10Y-0.4%-12.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.8%-13.0%-0.8%
TTM-16.5%-14.3%-2.2%
YOY-13.4%-14.2%+0.8%
3Y-13.6%-16.7%+3.1%
5Y-12.6%-17.3%+4.7%
10Y-0.4%-19.5%+19.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Altimmune Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Altimmune is operating .

  • Measures how much profit Altimmune makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • An Operating Margin of -405,100.0% means the company generated $-4,051.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Altimmune Inc:

  • The MRQ is -405,100.0%. The company is operating very inefficient. -2
  • The TTM is -454,560.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-405,100.0%TTM-454,560.0%+49,460.0%
TTM-454,560.0%YOY-224,282.9%-230,277.1%
TTM-454,560.0%5Y-216,101.1%-238,458.9%
5Y-216,101.1%10Y-112,346.4%-103,754.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-405,100.0%-221.2%-404,878.8%
TTM-454,560.0%-249.0%-454,311.0%
YOY-224,282.9%-205.1%-224,077.8%
3Y-351,341.5%-214.9%-351,126.6%
5Y-216,101.1%-344.1%-215,757.0%
10Y-112,346.4%-451.4%-111,895.0%
4.3.2.2. Operating Ratio

Measures how efficient Altimmune is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 4,364.00 means that the operating costs are $4,364.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Altimmune Inc:

  • The MRQ is 4,364.000. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4,915.350. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4,364.000TTM4,915.350-551.350
TTM4,915.350YOY2,916.215+1,999.135
TTM4,915.3505Y3,027.247+1,888.103
5Y3,027.24710Y1,620.443+1,406.804
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4,364.0002.088+4,361.912
TTM4,915.3502.776+4,912.574
YOY2,916.2153.043+2,913.172
3Y4,932.8343.525+4,929.309
5Y3,027.2474.724+3,022.523
10Y1,620.4436.443+1,614.000
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Altimmune Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Altimmune is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 15.85 means the company has $15.85 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Altimmune Inc:

  • The MRQ is 15.846. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.282. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ15.846TTM14.282+1.564
TTM14.282YOY15.379-1.097
TTM14.2825Y16.226-1.944
5Y16.22610Y12.375+3.851
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.8463.678+12.168
TTM14.2823.745+10.537
YOY15.3794.138+11.241
3Y14.0884.658+9.430
5Y16.2265.746+10.480
10Y12.3756.147+6.228
4.4.3.2. Quick Ratio

Measures if Altimmune is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • A Quick Ratio of 25.62 means the company can pay off $25.62 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Altimmune Inc:

  • The MRQ is 25.623. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 23.700. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ25.623TTM23.700+1.923
TTM23.700YOY20.841+2.858
TTM23.7005Y21.580+2.120
5Y21.58010Y16.818+4.761
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ25.6232.960+22.663
TTM23.7003.182+20.518
YOY20.8413.794+17.047
3Y20.3344.380+15.954
5Y21.5805.710+15.870
10Y16.8186.488+10.330
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Altimmune Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Altimmune assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Altimmune to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10 means that Altimmune assets are financed with 9.6% credit (debt) and the remaining percentage (100% - 9.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Altimmune Inc:

  • The MRQ is 0.096. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.107. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.096TTM0.107-0.011
TTM0.107YOY0.086+0.021
TTM0.1075Y0.101+0.006
5Y0.10110Y0.157-0.055
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0960.324-0.228
TTM0.1070.355-0.248
YOY0.0860.335-0.249
3Y0.0950.339-0.244
5Y0.1010.350-0.249
10Y0.1570.382-0.225
4.5.4.2. Debt to Equity Ratio

Measures if Altimmune is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • A Debt to Equity ratio of 10.6% means that company has $0.11 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Altimmune Inc:

  • The MRQ is 0.106. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.120. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.106TTM0.120-0.014
TTM0.120YOY0.094+0.026
TTM0.1205Y0.114+0.005
5Y0.11410Y0.428-0.314
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1060.383-0.277
TTM0.1200.436-0.316
YOY0.0940.414-0.320
3Y0.1050.452-0.347
5Y0.1140.464-0.350
10Y0.4280.509-0.081
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Altimmune generates.

  • Above 15 is considered overpriced but always compare Altimmune to the Biotechnology industry mean.
  • A PE ratio of -5.18 means the investor is paying $-5.18 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Altimmune Inc:

  • The EOD is -7.282. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.179. Based on the earnings, the company is expensive. -2
  • The TTM is -5.602. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.282MRQ-5.179-2.103
MRQ-5.179TTM-5.602+0.423
TTM-5.602YOY-5.670+0.067
TTM-5.6025Y-9.270+3.668
5Y-9.27010Y-32.650+23.380
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.282-2.107-5.175
MRQ-5.179-2.062-3.117
TTM-5.602-2.553-3.049
YOY-5.670-3.639-2.031
3Y-7.297-3.717-3.580
5Y-9.270-6.083-3.187
10Y-32.650-6.649-26.001
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Altimmune Inc:

  • The EOD is -8.465. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.020. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.516. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.465MRQ-6.020-2.444
MRQ-6.020TTM-6.516+0.495
TTM-6.516YOY-8.171+1.655
TTM-6.5165Y-11.914+5.398
5Y-11.91410Y-22.754+10.840
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.465-3.030-5.435
MRQ-6.020-2.736-3.284
TTM-6.516-3.704-2.812
YOY-8.171-4.267-3.904
3Y-9.475-5.095-4.380
5Y-11.914-8.527-3.387
10Y-22.754-9.201-13.553
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Altimmune is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.85 means the investor is paying $2.85 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Altimmune Inc:

  • The EOD is 4.011. Based on the equity, the company is fair priced.
  • The MRQ is 2.853. Based on the equity, the company is underpriced. +1
  • The TTM is 3.714. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.011MRQ2.853+1.158
MRQ2.853TTM3.714-0.862
TTM3.714YOY3.146+0.568
TTM3.7145Y4.285-0.570
5Y4.28510Y18.371-14.087
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.0111.874+2.137
MRQ2.8531.858+0.995
TTM3.7142.170+1.544
YOY3.1462.468+0.678
3Y3.8842.567+1.317
5Y4.2853.666+0.619
10Y18.3714.364+14.007
4.6.2. Total Gains per Share

2.4. Latest News of Altimmune Inc

Does Altimmune Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Altimmune Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-20
21:22
Lilly, Novo, and Amgen set for key obesity trial readouts at upcoming ADA eventRead
2025-06-13
13:30
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific SessionsRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Altimmune Inc.

4.8.1. Institutions holding Altimmune Inc

Institutions are holding 47.867% of the shares of Altimmune Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31BlackRock Inc7.56440.00066135230-24075-0.3909
2025-03-31Vanguard Group Inc5.43410.00044407462-24150-0.5449
2025-03-31State Street Corp4.18160.00073391571-78446-2.2607
2025-03-31TANG CAPITAL MANAGEMENT LLC3.39060.7607275000000
2025-03-31Geode Capital Management, LLC2.10330.00071705885473792.8567
2025-03-31Ameriprise Financial Inc1.78030.0021443932-3810966-72.5222
2025-03-31Marshall Wace Asset Management Ltd1.44050.0074116833811028211683.2593
2025-03-31Two Sigma Investments LLC1.41520.0123114781654251389.6267
2025-03-31Knoll Capital Management LP1.38283.6478112152400
2025-03-31Millennium Management LLC1.37020.0031111299765662221.522
2025-03-31Susquehanna International Group, LLP1.32670.00091076064575145114.818
2025-03-31Bellevue Group AG1.3030.1184105679311134711.7772
2025-03-31Schroder Investment Management Group1.18590.0052961884533563124.5708
2024-12-31UBS Group AG0.88720.001719555437100154.7503
2025-03-31Morgan Stanley - Brokerage Accounts0.81030.0002657247-264575-28.7013
2025-03-31Northern Trust Corp0.7850.0005636706-29210-4.3864
2025-03-31Dimensional Fund Advisors, Inc.0.60720.0006492469-140972-22.255
2024-12-31D. E. Shaw & Co LP0.56690.0024459833-298171-39.3363
2025-03-31Goldman Sachs Group Inc0.48130.0003390335-135835-25.8158
2025-03-31RFG Advisory Group, LLC0.40.04383243973243970
Total 38.41654.608931158340-366473-1.2%

4.9.2. Funds holding Altimmune Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv2.7580.0007223690300
2025-05-31iShares Russell 2000 ETF2.22930.016180813700
2025-05-31SPDR® S&P Biotech ETF2.03830.1913165319697860.5955
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.4090.0059114281723280.2041
2025-03-31Fidelity Small Cap Index0.87340.01477084093020.0426
2025-05-31iShares Biotechnology ETF0.56230.049645602900
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.50670.005441093100
2025-04-30Fidelity Extended Market Index0.48070.0057389846-3726-0.9467
2025-04-30Vanguard Russell 2000 ETF0.43440.0157352331197405.9352
2025-05-31iShares Russell 2000 Growth ETF0.41470.016533634800
2025-04-30International Biotechnology Ord0.37010.5396300214-661670-68.789
2025-05-31iShares Russell 2000 Value ETF0.36760.015129818800
2025-05-31State St Russell Sm Cap® Indx SL Cl I0.3060.015624820000
2025-04-30Vanguard Health Care ETF0.27520.0064223242-2106-0.9346
2025-03-31Vanguard Explorer Inv0.24220.00519642900
2025-04-30Schwab Small Cap Index0.22030.016117868256693.2766
2025-03-31NT R2000 Index Fund - NL0.21260.01481724183280.1906
2025-03-31Extended Equity Market Fund K0.18830.00581526944680.3074
2025-05-30Dimensional US Core Equity 2 ETF0.18450.002514968100
2025-05-29Direxion Daily S&P Biotech Bull 3X ETF0.18110.1356146915-3592-2.3866
Total 14.25471.07811561610-632473-5.5%

5.3. Insider Transactions

Insiders are holding 0.761% of the shares of Altimmune Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-03-13Gregory L WeaverBUY100005.2
2024-08-19David DrutzSELL160116.9
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets157,263
Total Liabilities15,101
Total Stockholder Equity142,162
 As reported
Total Liabilities 15,101
Total Stockholder Equity+ 142,162
Total Assets = 157,263

Assets

Total Assets157,263
Total Current Assets155,262
Long-term Assets2,001
Total Current Assets
Cash And Cash Equivalents 49,104
Short-term Investments 100,722
Net Receivables 507
Other Current Assets 4,929
Total Current Assets  (as reported)155,262
Total Current Assets  (calculated)155,262
+/-0
Long-term Assets
Property Plant Equipment 384
Long-term Assets Other 1,617
Long-term Assets  (as reported)2,001
Long-term Assets  (calculated)2,001
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities9,798
Long-term Liabilities5,303
Total Stockholder Equity142,162
Total Current Liabilities
Accounts payable 1,077
Other Current Liabilities 7,644
Total Current Liabilities  (as reported)9,798
Total Current Liabilities  (calculated)8,721
+/- 1,077
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,587
Long-term Liabilities Other 3,961
Long-term Liabilities  (as reported)5,303
Long-term Liabilities  (calculated)5,548
+/- 245
Total Stockholder Equity
Common Stock8
Retained Earnings -580,965
Accumulated Other Comprehensive Income -5,003
Other Stockholders Equity 728,122
Total Stockholder Equity (as reported)142,162
Total Stockholder Equity (calculated)142,162
+/-0
Other
Capital Stock8
Cash and Short Term Investments 149,826
Common Stock Shares Outstanding 75,548
Liabilities and Stockholders Equity 157,263
Net Debt -49,104
Net Invested Capital 142,162
Net Working Capital 145,464



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-30
> Total Assets 
202
69,722
70,087
70,497
70,740
71,164
71,739
72,375
19,400
72,493
66,611
62,223
53,756
50,305
56,391
53,724
43,021
41,970
34,065
28,482
23,864
21,615
27,199
23,875
26,316
21,640
22,804
24,754
23,808
23,411
22,741
21,972
24,587
20,619
17,139
14,374
15,223
23,350
21,978
25,465
22,616
20,896
19,862
18,735
27,931
140,539
224,739
20,728
90,842
74,346
63,030
63,030
52,102
52,861
54,751
54,751
61,976
56,388
54,058
54,233
102,544
232,995
245,115
264,251
257,261
236,907
218,865
205,660
209,906
225,277
206,928
187,083
183,316
166,573
210,640
188,358
173,346
147,864
139,306
157,263
157,263139,306147,864173,346188,358210,640166,573183,316187,083206,928225,277209,906205,660218,865236,907257,261264,251245,115232,995102,54454,23354,05856,38861,97654,75154,75152,86152,10263,03063,03074,34690,84220,728224,739140,53927,93118,73519,86220,89622,61625,46521,97823,35015,22314,37417,13920,61924,58721,97222,74123,41123,80824,75422,80421,64026,31623,87527,19921,61523,86428,48234,06541,97043,02153,72456,39150,30553,75662,22366,61172,49319,40072,37571,73971,16470,74070,49770,08769,722202
   > Total Current Assets 
202
69,722
70,087
70,497
70,740
71,164
71,739
72,375
10,000
64,184
58,475
38,540
32,878
30,548
46,142
45,031
33,578
32,060
24,217
18,426
14,376
12,302
23,584
20,413
22,940
18,337
19,613
21,529
20,683
20,379
19,796
19,068
21,692
17,766
14,339
11,586
12,433
20,585
19,251
22,739
19,906
18,246
17,227
16,137
25,399
138,036
222,270
18,292
16,996
26,122
23,466
23,466
11,866
11,966
39,372
39,372
46,105
41,624
39,395
39,637
87,970
218,132
230,257
245,192
238,625
218,263
204,126
191,093
195,504
211,004
192,813
173,111
169,532
152,964
209,626
187,515
171,186
145,759
137,254
155,262
155,262137,254145,759171,186187,515209,626152,964169,532173,111192,813211,004195,504191,093204,126218,263238,625245,192230,257218,13287,97039,63739,39541,62446,10539,37239,37211,96611,86623,46623,46626,12216,99618,292222,270138,03625,39916,13717,22718,24619,90622,73919,25120,58512,43311,58614,33917,76621,69219,06819,79620,37920,68321,52919,61318,33722,94020,41323,58412,30214,37618,42624,21732,06033,57845,03146,14230,54832,87838,54058,47564,18410,00072,37571,73971,16470,74070,49770,08769,722202
       Cash And Cash Equivalents 
6
1,471
1,398
1,323
1,003
764
675
467
7,100
60,337
40,583
19,239
14,152
10,141
19,752
17,245
9,273
4,188
2,674
735
682
2,718
11,785
9,708
14,161
10,406
11,237
15,304
11,777
14,726
12,702
12,873
15,790
15,943
10,481
9,535
11,265
19,620
18,643
15,725
18,412
17,389
15,570
14,236
23,158
69,107
153,995
15,782
8,368
17,117
8,769
8,769
4,171
7,964
33,719
33,719
41,672
10,972
8,963
11,275
64,742
143,495
115,918
149,932
174,102
174,864
190,301
179,947
135,858
127,465
111,097
104,690
102,352
86,855
135,158
78,978
57,128
31,474
36,926
49,104
49,10436,92631,47457,12878,978135,15886,855102,352104,690111,097127,465135,858179,947190,301174,864174,102149,932115,918143,49564,74211,2758,96310,97241,67233,71933,7197,9644,1718,7698,76917,1178,36815,782153,99569,10723,15814,23615,57017,38918,41215,72518,64319,62011,2659,53510,48115,94315,79012,87312,70214,72611,77715,30411,23710,40614,1619,70811,7852,7186827352,6744,1889,27317,24519,75210,14114,15219,23940,58360,3377,1004676757641,0031,3231,3981,4716
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
12,154
6,416
4,813
3,107
3,191
6,774
6,178
7,382
3,137
3,137
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,277
0
66,842
66,811
66,811
34
34
3,534
3,534
592
34
0
0
0
28,226
28,277
21,644
15,484
63,283
100,006
76,575
43,724
25,021
0
0
48,898
74,362
73,783
61,039
57,602
53,924
62,698
103,046
107,780
107,906
94,965
100,722
100,72294,965107,906107,780103,04662,69853,92457,60261,03973,78374,36248,8980025,02143,72476,575100,00663,28315,48421,64428,27728,226000345923,5343,534343466,81166,81166,84209,277000000000000000000000003,1373,1377,3826,1786,7743,1913,1074,8136,41612,1540000000000
       Net Receivables 
0
0
0
0
0
0
0
1,456
2,500
3,219
5,246
6,563
8,163
11,456
10,282
11,051
16,033
18,723
18,701
16,938
12,934
8,662
9,684
8,862
7,354
6,384
7,446
5,422
8,231
5,289
6,547
5,580
5,235
1,613
3,627
1,650
617
304
408
6,568
1,178
660
1,475
1,437
1,822
1,578
1,191
2,042
7,145
7,964
10,168
10,168
6,426
3,524
4,471
4,471
3,710
1,981
1,650
5,984
6,689
10,010
12,373
12,699
11,351
11,050
5,838
6,073
6,095
4,353
2,541
3,370
3,715
4,529
4,853
2,579
3,012
3,340
3,117
507
5073,1173,3403,0122,5794,8534,5293,7153,3702,5414,3536,0956,0735,83811,05011,35112,69912,37310,0106,6895,9841,6501,9813,7104,4714,4713,5246,42610,16810,1687,9647,1452,0421,1911,5781,8221,4371,4756601,1786,5684083046171,6503,6271,6135,2355,5806,5475,2898,2315,4227,4466,3847,3548,8629,6848,66212,93416,93818,70118,72316,03311,05110,28211,4568,1636,5635,2463,2192,5001,4560000000
       Other Current Assets 
196
68,251
68,689
69,175
69,738
70,400
0
71,908
400
628
492
6,323
5,749
5,844
12,917
9,961
2,095
1,766
973
752
760
922
2,114
1,842
1,425
1,547
931
802
675
364
547
614
668
210
231
401
551
661
199
446
316
196
182
464
419
825
420
204
1,449
1,007
4,529
4,529
677
444
1,183
1,183
723
444
504
733
1,055
1,343
1,961
5,985
9,447
7,329
13,397
5,073
10,553
4,824
5,392
3,978
5,822
7,656
6,958
2,871
3,266
3,039
2,246
4,929
4,9292,2463,0393,2662,8716,9587,6565,8223,9785,3924,82410,5535,07313,3977,3299,4475,9851,9611,3431,0557335044447231,1831,1834446774,5294,5291,0071,4492044208254194641821963164461996615514012312106686145473646758029311,5471,4251,8422,1149227607529731,7662,0959,96112,9175,8445,7496,32349262840071,908070,40069,73869,17568,68968,251196
   > Long-term Assets 
0
0
0
0
0
0
0
0
9,400
8,309
8,136
23,683
20,879
19,757
10,249
8,692
9,443
9,910
9,848
10,057
9,488
9,313
3,615
3,463
3,376
3,303
3,191
3,225
3,124
3,032
2,946
2,905
2,894
2,853
2,800
2,788
2,790
2,764
2,728
2,726
2,710
2,650
2,636
2,598
2,532
2,502
2,469
2,436
73,847
48,224
39,564
39,564
40,236
40,895
15,378
15,378
15,871
14,764
14,663
14,596
14,573
14,864
14,858
19,059
18,636
18,644
14,739
14,567
14,402
14,273
14,115
13,972
13,784
13,609
1,114
843
2,160
2,105
2,052
2,001
2,0012,0522,1052,1608431,11413,60913,78413,97214,11514,27314,40214,56714,73918,64418,63619,05914,85814,86414,57314,59614,66314,76415,87115,37815,37840,89540,23639,56439,56448,22473,8472,4362,4692,5022,5322,5982,6362,6502,7102,7262,7282,7642,7902,7882,8002,8532,8942,9052,9463,0323,1243,2253,1913,3033,3763,4633,6159,3139,48810,0579,8489,9109,4438,69210,24919,75720,87923,6838,1368,3099,40000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
6,000
6,716
6,571
6,289
6,386
6,191
5,313
5,211
5,909
6,208
6,262
6,481
6,182
6,042
1,178
1,061
974
901
789
702
626
553
484
457
460
430
386
381
387
362
326
324
308
248
234
196
184
154
121
88
293
280
603
603
1,476
1,407
1,343
1,343
1,955
1,880
1,803
1,744
1,687
1,982
1,961
6,064
4,751
4,718
1,448
1,337
1,236
1,172
1,081
1,007
882
765
1,014
544
483
446
413
384
3844134464835441,0147658821,0071,0811,1721,2361,3371,4484,7184,7516,0641,9611,9821,6871,7441,8031,8801,9551,3431,3431,4071,476603603280293881211541841962342483083243263623873813864304604574845536267027899019741,0611,1786,0426,1826,4816,2626,2085,9095,2115,3136,1916,3866,2896,5716,7166,00000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
2,308
2,503
2,503
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
35,399
9,335
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000009,33535,3992,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,5032,5032,308000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
1,300
1,333
1,313
1,222
1,198
1,128
925
875
908
930
929
918
855
833
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
430
0
0
0
17,821
0
0
15,668
14,955
15,198
38,132
38,586
38,722
38,722
38,349
38,339
13,852
13,852
13,760
12,742
12,732
12,738
12,786
12,795
12,824
12,879
12,956
12,994
12,419
12,419
12,419
12,419
12,419
12,419
12,419
12,419
0
0
0
0
0
0
00000012,41912,41912,41912,41912,41912,41912,41912,41912,99412,95612,87912,82412,79512,78612,73812,73212,74213,76013,85213,85238,33938,34938,72238,72238,58638,13215,19814,95515,6680017,82100043000000000000000008338559189299309088759251,1281,1981,2221,3131,3331,30000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
175
150
131
0
0
0
0
0
0
0
0
22
0
0
0
1,972
0
0
0
22
0
73,553
47,944
38,961
225
411
1,149
184
170
156
142
129
115
101
87
977
115
929
932
74
61
46
682
19
0
0
1
0
0
0
0
0
0
00000010019682466174932929115977871011151291421561701841,14941122538,96147,94473,5530220001,9720002200000000131150175000000000000000000000000000
> Total Liabilities 
179
13,758
411
14,195
14,155
14,277
14,625
14,921
31,200
28,492
26,039
26,102
39,031
39,137
37,428
37,150
32,690
35,483
32,181
33,691
33,462
33,022
14,988
13,040
12,243
7,102
6,952
10,983
10,262
10,860
11,068
12,030
11,366
9,265
9,804
6,049
4,359
5,244
3,704
5,442
4,280
3,224
3,213
3,108
3,680
4,156
205,280
2,677
14,866
25,516
14,353
14,353
16,292
13,178
6,438
6,438
5,751
7,004
8,538
12,337
23,022
33,289
19,239
17,813
15,983
27,643
19,730
20,792
15,371
20,248
21,635
19,351
15,602
16,176
16,541
15,421
20,815
14,487
15,798
15,101
15,10115,79814,48720,81515,42116,54116,17615,60219,35121,63520,24815,37120,79219,73027,64315,98317,81319,23933,28923,02212,3378,5387,0045,7516,4386,43813,17816,29214,35314,35325,51614,8662,677205,2804,1563,6803,1083,2133,2244,2805,4423,7045,2444,3596,0499,8049,26511,36612,03011,06810,86010,26210,9836,9527,10212,24313,04014,98833,02233,46233,69132,18135,48332,69037,15037,42839,13739,03126,10226,03928,49231,20014,92114,62514,27714,15514,19541113,758179
   > Total Current Liabilities 
179
179
411
617
576
698
1,046
1,342
18,100
10,813
8,997
9,731
15,418
29,439
35,873
33,761
31,217
16,330
13,466
14,380
12,691
30,033
6,163
6,702
5,929
3,692
4,615
5,314
5,659
6,971
7,488
7,788
7,722
5,413
6,796
3,465
2,831
3,885
2,582
4,537
3,335
2,381
2,179
2,640
3,269
3,728
204,838
2,235
5,528
4,180
3,840
3,840
7,067
8,345
4,527
4,527
3,480
2,467
3,923
6,045
4,917
6,294
12,020
9,824
9,096
19,127
18,276
19,124
13,845
15,742
17,054
14,951
11,437
11,871
12,143
11,333
15,155
8,638
10,468
9,798
9,79810,4688,63815,15511,33312,14311,87111,43714,95117,05415,74213,84519,12418,27619,1279,0969,82412,0206,2944,9176,0453,9232,4673,4804,5274,5278,3457,0673,8403,8404,1805,5282,235204,8383,7283,2692,6402,1792,3813,3354,5372,5823,8852,8313,4656,7965,4137,7227,7887,4886,9715,6595,3144,6153,6925,9296,7026,16330,03312,69114,38013,46616,33031,21733,76135,87329,43915,4189,7318,99710,81318,1001,3421,046698576617411179179
       Short-term Debt 
175
106
0
0
83
83
0
-2,175
11,800
4,000
4,000
4,000
4,000
16,933
17,378
17,777
17,256
0
0
0
0
20,058
0
0
0
0
0
1,053
455
1,890
2,081
2,329
2,168
1,000
2,092
1,000
1,000
993
746
498
249
2
538
468
799
1,151
459
0
50
50
50
50
1,311
1,467
72
72
410
358
259
266
905
328
357
366
375
402
411
421
431
442
452
463
474
485
496
508
345
313
279
0
027931334550849648547446345244243142141140237536635732890526625935841072721,4671,3115050505004591,15179946853822494987469931,0001,0002,0921,0002,1682,3292,0811,8904551,0530000020,058000017,25617,77717,37816,9334,0004,0004,0004,00011,800-2,1750838300106175
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
861
0
0
0
1,083
0
0
0
985
0
620
640
650
666
1,895
0
72
227
164
105
0
0
632
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000632001051642277201,89566665064062009850001,08300086100000000000000000000000000000000000000
       Accounts payable 
4
14
7
55
43
12
0
355
700
1,775
1,394
1,434
3,721
3,206
3,871
3,409
2,573
1,030
1,934
5,957
8,403
6,732
3,128
3,924
2,483
446
1,446
1,411
2,063
1,847
1,697
1,290
2,993
1,159
1,128
472
437
282
391
537
208
306
521
166
711
615
2,005
839
1,131
495
3,754
129
245
151
4,456
373
270
50
18
930
195
875
612
418
1,421
6
2,034
2,205
2,872
1,419
4,804
5,238
4,035
3,046
2,070
3,760
2,688
1,133
211
1,077
1,0772111,1332,6883,7602,0703,0464,0355,2384,8041,4192,8722,2052,03461,42141861287519593018502703734,4561512451293,7544951,1318392,0056157111665213062085373912824374721,1281,1592,9931,2901,6971,8472,0631,4111,4464462,4833,9243,1286,7328,4035,9571,9341,0302,5733,4093,8713,2063,7211,4341,3941,77570035501243557144
       Other Current Liabilities 
0
116
262
562
106
106
0
116
5,600
5,038
3,603
4,297
7,697
9,300
14,625
12,575
11,388
15,300
11,532
8,423
4,288
3,243
3,035
2,778
3,447
3,246
2,655
2,850
3,142
3,234
2,329
3,294
2,054
2,782
3,234
1,931
1,394
2,553
1,444
3,502
2,878
2,075
1,121
2,474
2,558
3,114
199,216
1,395
4,315
3,616
36
3,641
5,478
6,707
195
4,063
2,768
2,039
3,584
4,802
3,783
5,071
11,032
9,020
7,242
18,699
6,090
16,498
10,542
13,881
10,629
9,250
7,402
8,340
9,577
7,065
12,122
7,192
9,978
7,644
7,6449,9787,19212,1227,0659,5778,3407,4029,25010,62913,88110,54216,4986,09018,6997,2429,02011,0325,0713,7834,8023,5842,0392,7684,0631956,7075,4783,641363,6164,3151,395199,2163,1142,5582,4741,1212,0752,8783,5021,4442,5531,3941,9313,2342,7822,0543,2942,3293,2343,1422,8502,6553,2463,4472,7783,0353,2434,2888,42311,53215,30011,38812,57514,6259,3007,6974,2973,6035,0385,60011601061065622621160
   > Long-term Liabilities 
0
13,579
0
13,579
13,579
13,579
0
13,579
13,100
17,679
17,042
16,371
23,614
9,699
1,555
3,389
1,473
19,153
18,714
19,311
20,771
2,990
8,825
6,337
6,313
3,410
2,336
5,669
4,603
3,890
3,579
4,242
3,644
3,852
3,008
2,583
1,528
1,359
1,122
905
944
843
1,034
468
412
427
443
443
9,338
21,335
10,513
10,513
9,226
4,834
1,911
1,911
2,271
4,537
4,615
6,291
18,105
26,996
7,218
7,989
6,887
8,516
1,454
1,668
1,526
4,506
4,581
4,400
4,165
4,305
4,398
4,088
5,660
5,849
5,330
5,303
5,3035,3305,8495,6604,0884,3984,3054,1654,4004,5814,5061,5261,6681,4548,5166,8877,9897,21826,99618,1056,2914,6154,5372,2711,9111,9114,8349,22610,51310,51321,3359,3384434434274124681,0348439449051,1221,3591,5282,5833,0083,8523,6444,2423,5793,8904,6035,6692,3363,4106,3136,3378,8252,99020,77119,31118,71419,1531,4733,3891,5559,69923,61416,37117,04217,67913,10013,579013,57913,57913,579013,5790
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,235
1,984
1,764
1,704
1,460
1,218
974
730
485
240
0
0
0
0
0
0
0
0
0
0
0
617
4,618
4,575
3,776
4,285
1,942
1,852
2,317
2,212
1,787
1,865
1,791
1,715
1,926
1,828
1,719
1,617
1,566
1,454
1,668
1,526
4,506
0
4,400
4,165
0
0
0
0
0
0
0
00000004,1654,40004,5061,5261,6681,4541,5661,6171,7191,8281,9261,7151,7911,8651,7872,2122,3171,8521,9424,2853,7764,5754,618617000000000002404857309741,2181,4601,7041,7641,9842,235000000000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,238
9,282
5,955
510
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000005105,9559,2828,2380000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
258
0
0
0
229
0
0
0
196
443
223
4,196
3,974
8,600
8,132
4,289
1,409
359
400
2,985
3,130
4,875
16,760
25,435
7,218
7,989
6,887
8,516
331
652
622
4,506
3,909
0
3,736
4,002
0
0
0
0
0
0
0000004,0023,73603,9094,5066226523318,5166,8877,9897,21825,43516,7604,8753,1302,9854003591,4094,2898,1328,6003,9744,19622344319600022900025800000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,313
3,410
2,336
2,878
2,055
1,546
1,296
2,201
1,849
2,286
1,689
1,496
715
852
629
420
482
228
492
0
0
0
0
0
8,720
8,479
5,938
5,440
4,431
2,892
59
59
59
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000005959592,8924,4315,4405,9388,4798,720000004922284824206298527151,4961,6892,2861,8492,2011,2961,5462,0552,8782,3363,4106,313000000000000000000000000
> Total Stockholder Equity
23
55,964
69,676
56,302
56,586
56,887
0
57,455
-11,800
44,001
40,572
36,121
14,725
11,168
18,963
16,574
10,331
6,487
1,884
-5,208
-9,597
-11,408
12,211
10,835
14,073
14,538
15,852
13,771
13,545
12,551
11,674
9,943
13,220
11,354
7,336
8,325
10,865
18,106
18,274
20,023
18,336
17,672
16,649
15,626
24,251
136,383
19,459
18,051
75,977
48,830
39,396
48,678
35,810
39,683
48,313
48,313
56,225
49,384
45,520
41,897
79,522
199,706
225,876
246,437
241,278
209,264
199,135
184,868
194,535
205,029
185,293
167,732
167,714
150,397
194,099
172,937
152,531
133,377
123,508
142,162
142,162123,508133,377152,531172,937194,099150,397167,714167,732185,293205,029194,535184,868199,135209,264241,278246,437225,876199,70679,52241,89745,52049,38456,22548,31348,31339,68335,81048,67839,39648,83075,97718,05119,459136,38324,25115,62616,64917,67218,33620,02318,27418,10610,8658,3257,33611,35413,2209,94311,67412,55113,54513,77115,85214,53814,07310,83512,211-11,408-9,597-5,2081,8846,48710,33116,57418,96311,16814,72536,12140,57244,001-11,80057,455056,88756,58656,30269,67655,96423
   Common Stock
0
1
1
1
1
1
0
1
0
2
2
2
2
2
3
3
3
3
3
3
3
3
5
5
5
5
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
7
7
7
2
2
2
2
4
0
1
1
1
2
2
2
3
3
4
4
4
4
4
4
5
5
5
5
5
5
7
7
7
7
7
8
87777755555544444433222111042222777666666666555555555555553333333322222010111110
   Retained Earnings 
-3
144
277
482
766
1,067
1,294
1,635
-81,300
-82,303
-87,403
-92,420
-114,273
-118,616
-123,818
-129,831
-136,676
-150,639
-156,311
-164,255
-170,648
-174,976
-189,892
-191,968
-194,405
-194,439
-193,689
-196,369
-197,126
-197,340
-198,610
-200,721
-201,957
-205,903
-210,328
-212,586
-213,025
-217,654
-220,283
-218,820
-221,161
-222,486
-223,724
-224,951
-216,906
-107,671
-29,870
-32,067
-38,949
-68,854
-77,685
-77,685
-89,997
-92,348
-116,856
-116,856
-122,340
-133,279
-137,376
-141,262
-158,029
-175,799
-186,421
-210,945
-235,771
-269,282
-293,171
-312,601
-332,708
-356,224
-377,884
-397,958
-414,019
-434,690
-466,331
-490,725
-515,365
-538,210
-561,390
-580,965
-580,965-561,390-538,210-515,365-490,725-466,331-434,690-414,019-397,958-377,884-356,224-332,708-312,601-293,171-269,282-235,771-210,945-186,421-175,799-158,029-141,262-137,376-133,279-122,340-116,856-116,856-92,348-89,997-77,685-77,685-68,854-38,949-32,067-29,870-107,671-216,906-224,951-223,724-222,486-221,161-218,820-220,283-217,654-213,025-212,586-210,328-205,903-201,957-200,721-198,610-197,340-197,126-196,369-193,689-194,439-194,405-191,968-189,892-174,976-170,648-164,255-156,311-150,639-136,676-129,831-123,818-118,616-114,273-92,420-87,403-82,303-81,3001,6351,2941,067766482277144-3
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
207,232
207,810
208,526
209,111
209,663
210,102
210,496
210,878
215,393
217,472
217,877
221,126
224,105
235,980
238,781
239,065
239,490
240,151
240,367
240,571
241,151
244,035
49,323
50,112
120,662
122,393
121,656
125,358
130,844
137,072
170,208
183,314
183,604
187,683
187,915
188,209
242,580
380,544
417,338
462,418
482,084
483,582
497,342
502,505
532,398
566,551
0
570,786
586,908
0
0
0
0
0
0
0
0000000586,908570,7860566,551532,398502,505497,342483,582482,084462,418417,338380,544242,580188,209187,915187,683183,604183,314170,208137,072130,844125,358121,656122,393120,66250,11249,323244,035241,151240,571240,367240,151239,490239,065238,781235,980224,105221,126217,877217,472215,393210,878210,496210,102209,663209,111208,526207,810207,232000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
25
55,819
55,819
55,819
55,819
55,819
0
55,819
67,900
124,988
126,491
127,278
127,797
128,706
142,392
146,663
147,396
156,243
155,736
-6,580,888,745
-10,649,109,352
-12,538,241,024
200,847
201,571
207,232
207,810
208,526
209,111
209,663
210,102
210,496
210,878
215,393
217,472
217,877
221,126
224,105
235,980
238,781
239,065
239,490
240,151
240,367
240,571
241,151
244,035
71,035
50,112
120,662
114,154
-4,577
121,656
130,334
137,072
-5,040
170,208
183,604
187,683
187,915
188,209
242,580
380,544
417,338
462,418
482,084
483,582
497,342
502,505
532,398
566,551
568,399
570,786
586,908
590,206
665,427
668,816
673,081
676,425
689,864
728,122
728,122689,864676,425673,081668,816665,427590,206586,908570,786568,399566,551532,398502,505497,342483,582482,084462,418417,338380,544242,580188,209187,915187,683183,604170,208-5,040137,072130,334121,656-4,577114,154120,66250,11271,035244,035241,151240,571240,367240,151239,490239,065238,781235,980224,105221,126217,877217,472215,393210,878210,496210,102209,663209,111208,526207,810207,232201,571200,847-12,538,241,024-10,649,109,352-6,580,888,745155,736156,243147,396146,663142,392128,706127,797127,278126,491124,98867,90055,819055,81955,81955,81955,81955,81925



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue20
Cost of Revenue-238
Gross Profit20-218
 
Operating Income (+$)
Gross Profit20
Operating Expense-103,192
Operating Income-103,172-103,172
 
Operating Expense (+$)
Research Development82,226
Selling General Administrative20,966
Selling And Marketing Expenses0
Operating Expense103,192103,192
 
Net Interest Income (+$)
Interest Income8,074
Interest Expense-9
Other Finance Cost-0
Net Interest Income8,065
 
Pretax Income (+$)
Operating Income-103,172
Net Interest Income8,065
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-95,059-111,285
EBIT - interestExpense = -95,059
-95,059
-95,050
Interest Expense9
Earnings Before Interest and Taxes (EBIT)-95,050-95,050
Earnings Before Interest and Taxes (EBITDA)-94,812
 
After tax Income (+$)
Income Before Tax-95,059
Tax Provision-0
Net Income From Continuing Ops-95,059-95,059
Net Income-95,059
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses103,192
Total Other Income/Expenses Net8,113-8,065
 

Technical Analysis of Altimmune
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Altimmune. The general trend of Altimmune is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Altimmune's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Altimmune Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Altimmune Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 7.1699 < 7.42 < 7.83.

The bearish price targets are: 6.16 > 6.13 > 5.15.

Know someone who trades $ALT? Share this with them.👇

Altimmune Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Altimmune Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Altimmune Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Altimmune Inc. The current macd is 0.40778941.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Altimmune price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Altimmune. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Altimmune price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Altimmune Inc Daily Moving Average Convergence/Divergence (MACD) ChartAltimmune Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Altimmune Inc. The current adx is 34.19.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Altimmune shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Altimmune Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Altimmune Inc. The current sar is 6.07539899.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Altimmune Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Altimmune Inc. The current rsi is 66.62. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Altimmune Inc Daily Relative Strength Index (RSI) ChartAltimmune Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Altimmune Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Altimmune price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Altimmune Inc Daily Stochastic Oscillator ChartAltimmune Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Altimmune Inc. The current cci is 101.59.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Altimmune Inc Daily Commodity Channel Index (CCI) ChartAltimmune Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Altimmune Inc. The current cmo is 39.23.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Altimmune Inc Daily Chande Momentum Oscillator (CMO) ChartAltimmune Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Altimmune Inc. The current willr is -20.67510549.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Altimmune is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Altimmune Inc Daily Williams %R ChartAltimmune Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Altimmune Inc.

Altimmune Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Altimmune Inc. The current atr is 0.5022527.

Altimmune Inc Daily Average True Range (ATR) ChartAltimmune Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Altimmune Inc. The current obv is 252,587,334.

Altimmune Inc Daily On-Balance Volume (OBV) ChartAltimmune Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Altimmune Inc. The current mfi is 82.70.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Altimmune Inc Daily Money Flow Index (MFI) ChartAltimmune Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Altimmune Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-11STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-10MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-16MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside

6.3. Candlestick Patterns

Altimmune Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Altimmune Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5066.625
Ma 20Greater thanMa 506.084
Ma 50Greater thanMa 1005.535
Ma 100Greater thanMa 2005.715
OpenGreater thanClose6.850
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Altimmune with someone you think should read this too:
  • Are you bullish or bearish on Altimmune? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Altimmune? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Altimmune Inc

I send you an email if I find something interesting about Altimmune Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Altimmune Inc.

Receive notifications about Altimmune Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.